The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population by unknown
ORIGINAL ARTICLE
The LRRK2 Arg1628Pro variant is a risk factor
for Parkinson’s disease in the Chinese population
Chin-Song Lu & Yah-Huei Wu-Chou &
Marina van Doeselaar & Erik J. Simons &
Hsiu-Chen Chang & Guido J. Breedveld &
Alessio Di Fonzo & Rou-Shayn Chen & Yi-Hsin Weng &
Szu-Chia Lai & Ben A. Oostra & Vincenzo Bonifati
Received: 4 June 2008 /Accepted: 13 July 2008 / Published online: 21 August 2008
# The Author(s) 2008
Abstract The c.G4883C variant in the leucine-rich repeat
kinase 2 (LRRK2) gene (protein effect: Arg1628Pro) has
been recently proposed as a second risk factor for sporadic
Parkinson’s disease in the Han Chinese population (after
the Gly2385Arg variant). In this paper, we analyze the
Arg1628Pro variant and the associated haplotype in a large
sample of 1,337 Han subjects (834 patients and 543
controls) ascertained from a single referral center in
Taiwan. In our sample, the Arg1628Pro allele was more
frequent among patients (3.8%) than among controls (1.8%;
p = 0.004, OR 2.13, 95% CI 1.29–3.52). Sixty heterozy-
gous and two homozygous carriers of the Arg1628Pro
variant were identified among the patients, of which only
one was also a carrier of the LRRK2 Gly2385Arg variant.
We also show that carriers of the Arg1628Pro variant share
a common, extended haplotype, suggesting a founder
effect. Parkinson’s disease onset age was similar in patients
who carried the Arg1628Pro variant and in those who did
not carry it. Our data support the contention that the
Arg1628Pro variant is a second risk factor for Parkinson’s
disease in the Han Chinese population. Adding the
estimated effects of Arg1628Pro (population attributable
risk [PAR] ~4%) and Gly2385Arg variants (PAR ~6%)
yields a total PAR of ~10%.
Keywords Parkinson’s disease . Genetics . LRRK2 .
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Introduction
The identification of mutations in the leucine-rich repeat
kinase 2 (LRRK2) gene as a cause of autosomal dominant
Parkinson’s disease (PD) opened a novel era for the
understanding of the causes and mechanisms of this
disorder [1, 2]. LRRK2 (particularly, the Gly2019Ser
mutation) gave proof of principle of a common genetic
cause of typical late-onset PD, but it also yielded the first
variant, Gly2385Arg, a frequent polymorphism in different
Asian populations, which acts as a risk factor for the
common, sporadic form of PD in those populations [3].
In search for population-specific biologically relevant
variants, we sequenced the complete LRRK2 coding region
in a number of PD patients from Taiwan [4]. This work
led to our initial identification of the association of
Gly2385Arg with PD, a finding that has been rapidly and
Neurogenetics (2008) 9:271–276
DOI 10.1007/s10048-008-0140-6
C.-S. Lu : R.-S. Chen :Y.-H. Weng : S.-C. Lai
Neuroscience Research Center, Chang Gung Memorial Hospital,
Chang Gung University,
Taipei, Taiwan
C.-S. Lu :H.-C. Chang : R.-S. Chen :Y.-H. Weng : S.-C. Lai
Department of Neurology, Chang Gung Memorial Hospital,
Taipei, Taiwan
Y.-H. Wu-Chou
Human Molecular Genetics Laboratory,
Chang Gung Memorial Hospital,
Taipei, Taiwan
M. van Doeselaar : E. J. Simons :G. J. Breedveld :A. Di Fonzo :
B. A. Oostra :V. Bonifati (*)
Department of Clinical Genetics,




Department of Neurology, Chang Gung Memorial Hospital,
No. 5, Fu-Shin Street,
Kweishan, Taoyuan 33305, Taiwan
e-mail: c81214@adm.cgmh.org.tw
consistently replicated in Chinese populations from Singa-
pore [5], Taiwan [6, 7], mainland China [8, 9], and in the
Japanese population [10].
Very recently, a different LRRK2 missense variant,
Arg1628Pro, was proposed as a second risk factor for
sporadic PD in the Han Chinese population (OR 1.84, 95%
CI 1.20–2.83, p = 0.006) [11]. In this study, we report the
results of the analysis of the Arg1628Pro variant in a large,
independent sample of PD cases and controls of Han
Chinese ethnicity.
Materials and methods
The study sample consisted of 1,377 subjects of Han
Chinese ethnicity, ascertained at a single referral center in
Taiwan, and included 834 patients with a clinical diagnosis
of idiopathic PD and sporadic pattern of presentation (343
women, 491 men) and 543 control subjects (319 women,
224 men). For the patients, the average ages at last
examination and at disease onset were 65.7 ± 11.8 years
(range 24–97) and 55.6 ± 12.1 years (range 12–94),
respectively. The average disease duration was 10.1 ±
6.24 years (range 1–30). The clinical diagnosis of PD was
established according to published criteria [12]. A first
subgroup of 608 PD cases was previously screened by us
for the LRRK2 Ile2012Thr, Gly2019Ser, and Ile2020Thr
mutation and proved to be negative [13]. In cases with
disease onset before the age of 40 years, the parkin and
PINK1 genes were screened by single-strand conformation
polymorphism, and no mutations were found. The control
subjects were free from PD, matched to the patients by
ethnicity, collected at the same center, and originating from
the same geographical areas. They were ascertained among
the spouses of PD patients, spouses of patients with
unrelated diseases, and healthy volunteers. The mean age
at sampling for controls was 51.9 ± 18.4 years, range 11–
87, which is slightly, but significantly younger than the
average age at onset in the cases. The project was approved
from the local ethical authorities, and written informed
consent was obtained from all subjects.
Genomic DNA was isolated from peripheral blood using
standard protocols. In the whole sample of cases and
controls, the LRRK2 c.G4883C variant in exon 34 (single
nucleotide polymorphism [SNP] accession no. rs33949390,
predicted protein effect: Arg1628Pro) was screened by a
TaqMan allelic discrimination method and Assays-by-
Design on an Applied Biosystems 7300 Real Time PCR
System. Primers, probes, and experimental conditions are
available on request.
For genotyping quality control, multiple positive and
negative controls for the c.G4883C variant were included in
each polymerase chain reaction plate. Furthermore, 176
cases and 181 controls were also genotyped for Arg1628-
Pro and other variants located in exon 34 by direct
sequencing in both strands, as described previously [14],
yielding 100% concordance with the results of the TaqMan
assay for the Arg1628Pro variant.
For haplotype analysis, we first examined the complete
coding region of LRRK2 and exon–intron boundaries,
sequenced previously by us in two heterozygous carriers of
the c.G4883C (Arg1628Pro) variant [4]. All the variants
detected were tested in one additional heterozygous and two
homozygous Arg1628Pro carriers detected in this study.
Furthermore, five coding SNPs located in exon 5
(Leu153Leu, rs10878245), exon 34 (Gly1624Gly,
rs1427263; Lys1637Lys, rs11176013; Ser1647Thr,
rs11564148), and exon 49 (Met2397Thr, rs3761863) were
typed by direct sequencing in 46 PD patients who were
carriers of the Arg1628Pro variant, as well as in 87
Taiwanese subjects (44 PD patients and 43 controls) who
were not carrying Arg1628Pro. Haplotype analysis was
performed using Haploview ver. 1.4 [15]. Lastly, the c.
G4883C (Arg1628Pro) variant was typed by direct se-
quencing in 202 Caucasian subjects (106 PD patients and
96 controls, total 404 chromosomes). Sequencing was
performed using Big Dye Terminator chemistry ver.3.1
(Applied Biosystems). Fragments were loaded on an
ABI3100 and analyzed with DNA Sequencing Analysis
(ver.3.7) and SeqScape (ver.2.1) software (Applied Bio-
systems). All variants are named according to the LRRK2
complementary DNA sequence deposited in GenBank
(accession no. NM_198578).
For predicting the secondary structure of the region of
the LRRK2 protein containing the Arg1628 residue, we
used the PSIPRED ver.2.6 [16] and NPS [17] programs.
Statistical analyses included contingency tables and Stu-
dent’s test as appropriate. For the calculation of the
population attributable risk (PAR), the following formula
was used: P(OR − 1)/1 + P(OR − 1), where P is the
frequency of the risk genotype (heterozygous Arg1628Pro)
in the controls, considered to approximate the frequency of
the risk genotype in the general population and OR is the
odds ratio obtained in the case control comparison, used to
estimate the relative risk of PD for the carriers of the risk
genotype.
Results
The results of the association analysis are reported in the
table. Controls and cases were both in Hardy–Weinberg
equilibrium. The Arg1628Pro variant was detected in 62
cases (7.4%, two homozygous and 60 heterozygous) and in
20 controls (3.7%, all heterozygous). The Arg1628Pro
allele was significantly more frequent among patients (p =
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0.004, OR 2.13, 95% CI 1.29–3.52; Table 1). Using this
observed value of OR to estimate the relative risk and the
frequency of the risk genotype (heterozygous Arg1628Pro)
among controls as an estimate of its frequency in the
general population yields a PAR of ~4%.
The sequencing of LRRK2 exons and exon–intron
boundaries in two homozygous and three heterozygous
carriers of the Arg1628Pro variant revealed several,
previously reported intronic and exonic SNP variants
(Fig. 1a). Haplotypes in the two homozygous patients are
identical (Fig. 1a), and those in the three heterozygous
cases are also compatible with the presence of the same
shared haplotype across the whole LRRK2 gene. Further-
more, in 46 Taiwanese patients, who carried the Arg1628-
Pro variant, the analysis by Haploview detected association
of this variant always with the same haplotype (formed by
the C-A-G-A-C alleles of the Leu153Leu, Gly1624Gly,
Lys1637Lys, Ser1647Thr, and Met2397Thr variants). On
the other hand, this specific C-A-G-A-C haplotype was
estimated by Haploview at a frequency of 0.283 and 0.291
among Taiwanese PD patients and controls, who did not
carry the Arg1628Pro variant.
Fig. 1 a Haplotype containing
the Arg1628Pro variant. Exonic
variants are bolded and two
non-synonymous variants are
indicated by arrowheads. The
position of the Arg1628Pro var-
iant is indicated by an arrow in
the haplotype and in the LRRK2
domain structure shown below.
ank ankyrin-like repeat region,
LRR leucine-rich repeat region,
ROC Ras in complex proteins,
COR C-terminal of Roc, WD40
WD40 repeat-like domain. b
Alignment of LRRK2 protein
homologues in the region
corresponding to the human
Arg1628 residue
Table 1 Distribution of G4883C (Arg1628Pro) allelic and genotypic frequencies
Cases (n=834) Controls (n=543)
Genotypes Alleles Genotypes Alleles
G/G G/C C/C G C G/G G/C C/C G C
Number 772 60 2 1,604 64 523 20 0 1,066 20
Percentage 0.926 0.072 0.002 0.962 0.038 0.963 0.037 0.0 0.982 0.018
p value=0.004—comparison of allelic frequency in PD cases versus controls
p value=0.006—comparison of genotype frequency in PD cases versus controls (heterozygous and homozygous Arg1628Pro carriers combined)
p value=0.009—comparison of genotype frequency in PD cases versus controls (only heterozygous Arg1628Pro carriers)
Chi-square with Yates correction
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All the patients who were carriers of the Arg1628Pro
variant were tested for the presence of the Gly2385Arg
variant, by direct sequencing of LRRK2 exon 49. Only one
of the carriers of the Arg1628Pro variant (heterozygous)
was also a carrier of the heterozygous Gly2385Arg variant.
We did not detect the c.G4883C (Arg1628Pro) variant in
any of 404 Caucasian chromosomes (212 from PD patients
and 192 from controls).
PD average onset age in the 60 heterozygous carriers of
the Arg1628Pro variant was 55.4±10.3 years (range 35–
80), while in the 772 non-carriers, the onset age was 55.6±
12.2 (12–94; p=NS). Disease duration was 10.9±7.1 years
(1–30) and 10.1±6.2 (1–30) in carriers and non-carriers,
respectively (p=NS). The two patients homozygous carriers
of Arg1628Pro had PD onset at ages 38 and 55 and disease
duration of 15 and 18 years.
The mean age at examination in the 20 controls, who
were carriers of the Arg1628Pro heterozygous variant, was
49.2 years±18.3 (22–72), which is younger but not
significantly different than the mean onset age of PD in
the heterozygous carriers (p=0.064, Student’s t-test);
however, half of the control carriers were younger than
the mean onset age of PD in heterozygous carriers.
Discussion
Our results support the contention that the LRRK2
Arg1628Pro variant is a second risk factor for the common
forms of sporadic PD in the Chinese population (after the
Gly2385Arg variant). We neither detected the Arg1628Pro
variant in any of the 404 Caucasian chromosomes, nor was
the variant reported in the other LRRK2 studies in
Caucasians. Similar to Gly2385Arg [3], Arg1628Pro might
be therefore considered as a PD-associated population-
specific allele in the Han Chinese population. Interestingly,
in the previous report [11], the Arg1628Pro variant was not
detected among Japanese subjects, but the sample size was
limited (N=246), and further studies are warranted.
The results of our haplotype analyses, in keeping with
the data from the previous study [11], strongly suggest that
most carriers of the Arg1628Pro variant share an extended
haplotype, indicative of a founder effect.
Any given disease-associated variant might merely
represent a marker of another, biologically relevant variant,
which lies in linkage disequilibrium on the risk allele.
While Arg1628Pro is a non-conservative change in a highly
conserved residue (Fig. 1b), the associated haplotype
includes 11 intronic, five exonic silent, and two conserva-
tive variants (Ser1647Thr and Met2397Thr; Fig. 1a).
However, all these variants display much higher allele
frequencies than Arg1628Pro (our data not shown), and,
more importantly, these variants are also present in
Caucasian populations, where association with PD was
not detected in previous studies examining common LRRK2
variants using haplotype-tagging SNPs [18, 19]. We also
explored the frequency of three variants located in exon 34:
Gly1624Gly (rs1427263), Lys1637Lys (rs11176013), and
Ser1647Thr (rs11564148) in 176 cases and 181 controls
from this study (more than 700 chromosomes), but we
detected no association with PD (Gly1624Gly minor allele
frequency [MAF] 0.45 in cases and 0.53 in controls;
Lys1637Lys MAF 0.44 in cases and 0.49 in controls;
Ser1647Thr MAF 0.33 in cases and 0.32 in controls). From
all these arguments, we conclude that the Arg1628Pro
variant is most likely the biologically relevant variant,
responsible for the association with PD detected here and in
the previous, independent study [11].
Results of allelic association studies might be biased,
mainly by the use of small sample sizes, population
stratification, and genotyping errors [20], and replication
in independent, large samples is important. In order to
minimize these sources of biases, we tested a large sample
of ethnically matched cases and controls, recruited at only
one referral center; we adopted strict PD diagnostic criteria,
and we excluded familial PD cases; genotyping was
performed in only one laboratory using standard and
uniform genotyping platforms and rigorous systematic
quality controls. These considerations argue against the
existence of the above-mentioned biases. Furthermore, as
some of the control carriers of the variant might still
develop PD at later ages, the actual effect size (OR) of the
Arg1628Pro variant might be higher.
Contrary to the Arg2385Gly, the Arg1628Pro variant
replaces a highly conserved residue in the COR domain of
the LRRK2 protein (Fig. 1a,b). The COR domain (C-
terminal of Roc) is unique for the LRRK2 protein family
[21], where it is thought to mediate intramolecular signaling
between the N-terminal Roc-GTPase and the C-terminal
kinase domain of LRRK2 (Fig. 1a). Only one definitely
PD-causing mutation is known so far in the COR domain
(Tyr1699Cys). The Arg1628Pro variant replaces the posi-
tively charged arginine with a nonpolar Proline. Moreover,
Proline might change the local folding, as it is typically
acting by breaking α-helical conformation in proteins.
Analyses using the PSIPRED and NPS programs indicate
that the Arg1628 and the following 7–10 amino acids are
likely to adopt an α-helical conformation. Loss of the net
positive charge, change in α-helical content, or both might
affect the structure and function of the COR domain, with
the final effect of altering the regulation of the downstream
kinase activity of LRRK2. Functional studies are warranted
to understand the mechanisms of action of the Arg1628Pro
variant. As it is the case for the other PD-associated variant
in LRRK2 (Arg2385Gly), onset age of PD in cases who are
carriers and non-carriers of the Arg1628Pro variant does
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not differ, but further study might identify differences in
other clinical or patho-physiological features.
With only one exception, in our experience, the cases
that carry Arg1628Pro do not carry Arg2385Gly and vice
versa. These two variants are therefore located on different
alleles, and their impact at the population level will add to
each other. The patient who carries both LRRK2 risk
variants has a 16-year history of tremor-predominant PD,
which started at the age of 65 and responded well to L-
dopa, but with L-dopa-induced psychosis developing 7 years
after PD onset. DAT scan (99mTc-TRODAT SPECT)
showed decreased dopamine transporter activity. Before
the onset of motor symptoms, the patient developed
anosmia but no rapid eye movement (REM) sleep behavior
disorder. We also detected two cases who are homozygous
carriers of Arg1628Pro. These cases had PD onset at ages
38 and 55 and disease duration of 15 and 18 years. The first
has tremor-predominant, while the other has akinetic-rigid-
predominant PD type. Both responded well to L-dopa, but
L-dopa-induced psychosis developed 13 years after onset of
PD in the second. DAT scan (99mTc-TRODAT SPECT)
showed decreased dopamine transporter activity in both.
None of these developed hyposmia or REM sleep behavior
disorder. Further homozygous cases need to be identified in
order to answer the question whether carrying two copies of
the Arg1628Pro variant yields a younger or more aggres-
sive phenotype.
The PAR is the percentage of cases in a given
population, which are attributable to the effect of a given
etiologic factor (in this case, the risk allele), and which
could be prevented if the risk factor could be ideally
removed from the population. Using the observed frequen-
cy of the risk genotype (heterozygous Arg1628Pro) among
controls (0.037) and the observed value of OR (2.1) to
estimate the risk genotype frequency in the general
population and the relative risk, one can estimate a PAR
of ~4%. In the most populous nations of the world, the
number of PD cases among individuals over age 50 is
projected to more than double from the current
approximately four to nine million by the year 2030,
with the Chinese population contributing more that 50%
of these patients [22]. The Gly2385Arg variant is present
in ~5% of controls from Taiwan, and its size effect (OR) as
a risk factor for PD is around 2.2 in our Taiwanese study
[4] and in replication studies [3], allowing an estimate of
PAR of ~6% for the Gly2385Arg variant. Therefore,
considering the Arg1628Pro and Gly2385Arg variants
together, the coding variability in LRRK2 might account
for ~10% of PAR for this disease in China. The
identification of Arg1628Pro as a second risk factor for
PD constitutes therefore a further important step forward
in the dissection of the causes and mechanisms of PD.
Additional risk variants in LRRK2 or different genes might
exist in other populations, and further, extensive analyses
are warranted.
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